Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to address neurological health, focusing on both a novel multiple sclerosis (MS) therapy and a dietary supplement aimed at mitigating the effects of alcohol. The biopharmaceutical company, which specializes in innovative therapies for neurodegenerative and metabolic disorders, is developing Lucid-MS, an investigational treatment designed to protect and potentially restore the myelin sheath in MS patients, and unbuzzd, a proprietary supplement intended to support alcohol metabolism and reduce acute intoxication and hangover symptoms.
The company's approach to MS differs from conventional treatments that primarily modulate the immune system. Instead, Lucid-MS targets PAD2, an enzyme associated with myelin degradation, with the goal of preserving and possibly repairing the myelin sheath—the protective covering of nerve fibers that is damaged in MS. This mechanism could offer a new avenue for treating the underlying cause of the disease rather than just managing symptoms. Quantum BioPharma has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial of Lucid-MS, and is supporting its development through an imaging collaboration with Massachusetts General Hospital.
In parallel, the company is advancing unbuzzd, a proprietary dietary supplement that has shown promise in reducing acute intoxication and hangover effects. According to Quantum BioPharma, results from a randomized, placebo-controlled clinical trial support the product's efficacy. The company has spun out the over-the-counter version of unbuzzd to Unbuzzd Wellness Inc. (UWI), a company led by industry veterans, while retaining a 19.84% ownership stake in UWI as of March 31, 2026. The agreement with UWI includes royalty payments of 7% of sales from unbuzzd until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar or alternative formulations for pharmaceutical and medical uses.
This dual strategy underscores Quantum BioPharma's commitment to addressing significant unmet needs in neurological health. The potential impact of Lucid-MS could be profound for the estimated 2.8 million people worldwide living with MS, offering a treatment that may not only slow disease progression but also potentially reverse myelin damage. If successful in clinical trials, Lucid-MS could represent a paradigm shift in MS therapy, moving beyond immune modulation to direct neuroprotection and repair.
Similarly, unbuzzd addresses a widespread public health concern related to alcohol consumption, which is associated with numerous health risks and economic costs. By providing a supplement that may reduce intoxication and hangover severity, unbuzzd could appeal to a broad consumer market, potentially generating significant revenue for the company through royalties and ownership in UWI. The product's availability as an over-the-counter supplement also offers a more accessible option for individuals seeking to mitigate the effects of alcohol.
For investors, these developments highlight Quantum BioPharma's diversified pipeline, which balances high-risk, high-reward drug development with a consumer health product that has near-term commercial potential. The company's focus on innovative mechanisms and strategic partnerships, such as the imaging collaboration with Massachusetts General Hospital, enhances its credibility and ability to advance its research. As Quantum BioPharma progresses with its IND application for Lucid-MS and continues to support unbuzzd's market presence, the outcomes of these initiatives could significantly influence the company's trajectory and the broader landscape of neurological health treatments.
